CA2662535A1 - Method for reducing or alleviating inflammation in the digestive tract - Google Patents

Method for reducing or alleviating inflammation in the digestive tract Download PDF

Info

Publication number
CA2662535A1
CA2662535A1 CA002662535A CA2662535A CA2662535A1 CA 2662535 A1 CA2662535 A1 CA 2662535A1 CA 002662535 A CA002662535 A CA 002662535A CA 2662535 A CA2662535 A CA 2662535A CA 2662535 A1 CA2662535 A1 CA 2662535A1
Authority
CA
Canada
Prior art keywords
carboxy
ethylamino
imidazol
ace2
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002662535A
Other languages
English (en)
French (fr)
Inventor
Louis Anthony Tartaglia
Thomas Michael Barnes
Robert Mark Coopersmith
Scott Edward Malstrom
David William White
Dominic Picarella
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ore Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2662535A1 publication Critical patent/CA2662535A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
CA002662535A 2006-09-08 2007-09-07 Method for reducing or alleviating inflammation in the digestive tract Abandoned CA2662535A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US82507506P 2006-09-08 2006-09-08
US60/825,075 2006-09-08
US82780706P 2006-10-02 2006-10-02
US60/827,807 2006-10-02
PCT/US2007/077857 WO2008031014A1 (en) 2006-09-08 2007-09-07 Method for reducing or alleviating inflammation in the digestive tract

Publications (1)

Publication Number Publication Date
CA2662535A1 true CA2662535A1 (en) 2008-03-13

Family

ID=38670723

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002662535A Abandoned CA2662535A1 (en) 2006-09-08 2007-09-07 Method for reducing or alleviating inflammation in the digestive tract

Country Status (11)

Country Link
US (1) US20080234345A1 (https=)
EP (1) EP2059234B1 (https=)
JP (1) JP2010502736A (https=)
CN (1) CN101568331A (https=)
AT (1) ATE531362T1 (https=)
AU (1) AU2007292247A1 (https=)
CA (1) CA2662535A1 (https=)
DK (1) DK2059234T3 (https=)
ES (1) ES2376493T3 (https=)
IL (1) IL197362A0 (https=)
WO (1) WO2008031014A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2095819A1 (en) * 2008-02-28 2009-09-02 Maastricht University N-benzyl imidazole derivatives and their use as aldosterone synthase inhibitors
JP2011513491A (ja) * 2008-03-10 2011-04-28 オレ・ファーマシューティカルズ・インコーポレーテッド 近位消化管の障害の治療
WO2010093804A1 (en) * 2009-02-12 2010-08-19 Ore Pharmaceuticals, Inc. Ace2 inhibitors for reducing gastrointestinal adverse effects of cytotoxic agents
EP2543388A4 (en) * 2010-03-04 2013-11-27 Dainippon Sumitomo Pharma Co MEDICINAL PRODUCT FOR INFLAMMATORY ENDURANCE
PT2544679T (pt) 2010-03-12 2019-07-11 Omeros Corp Inibidores de pde-10 e composições e métodos relacionados
NZ716494A (en) 2014-04-28 2017-07-28 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
NZ630803A (en) 2014-04-28 2016-03-31 Omeros Corp Optically active pde10 inhibitor
MA41271A (fr) * 2014-12-26 2017-10-31 Celgene Alpine Invest Company Ii Llc Méthodes d'utilisation d'oligonucléotides antisens ciblant smad7
US9879002B2 (en) 2015-04-24 2018-01-30 Omeros Corporation PDE10 inhibitors and related compositions and methods
US9920045B2 (en) 2015-11-04 2018-03-20 Omeros Corporation Solid state forms of a PDE10 inhibitor
GB202116266D0 (en) * 2021-11-11 2021-12-29 Bicycletx Ltd Novel use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194556B1 (en) * 1997-12-11 2001-02-27 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therfor
CN1377259A (zh) * 1999-04-30 2002-10-30 千年药品公司 抑制ace－2的化合物及其使用方法
US7045532B2 (en) * 1999-04-30 2006-05-16 Millennium Pharmaceuticals, Inc. ACE-2 modulating compounds and methods of use thereof
WO2002098448A1 (en) 2001-06-04 2002-12-12 Human Genome Sciences, Inc. Methods and compositions for modulating ace-2 activity
GB0203061D0 (en) 2002-02-08 2002-03-27 Novartis Ag Organic compounds
BR0314713A (pt) * 2002-09-24 2005-07-26 Combinatorx Inc Processos e reagentes para o tratamento de doenças e distúrbios associados com nìveis aumentados de citocinas pró-inflamatórias
JP2006517969A (ja) * 2003-02-14 2006-08-03 コンビナトアールエックス インコーポレーティッド 免疫炎症性障害の治療のための組み合わせ療法
US20050203168A1 (en) * 2004-03-11 2005-09-15 The Regents Of The University Of Michigan Angiotensin converting enzyme inhibitor use for treatment and prevention of gastrointestinal disorders
WO2008031013A1 (en) * 2006-09-08 2008-03-13 Gene Logic Inc. Method for treating inflammatory diseases of the digestive tract

Also Published As

Publication number Publication date
ES2376493T3 (es) 2012-03-14
JP2010502736A (ja) 2010-01-28
ATE531362T1 (de) 2011-11-15
AU2007292247A1 (en) 2008-03-13
EP2059234A1 (en) 2009-05-20
WO2008031014A1 (en) 2008-03-13
AU2007292247A2 (en) 2009-03-26
DK2059234T3 (da) 2011-11-28
IL197362A0 (en) 2009-12-24
CN101568331A (zh) 2009-10-28
EP2059234B1 (en) 2011-11-02
US20080234345A1 (en) 2008-09-25

Similar Documents

Publication Publication Date Title
US7842709B2 (en) Method for treating inflammatory diseases of the digestive tract
EP2059234B1 (en) Method for reducing or alleviating inflammation in the digestive tract
US20120009183A1 (en) Method for treatment of pancreatitis
US20080300217A1 (en) Combination Therapy with Fumaric Acid Esters for the Treatment of Autoimmune and/or Inflammatory Disorders
CN106999593A (zh) 用于纤维化治疗的赛尼克韦罗组合疗法
US20210069192A1 (en) Use of neutrophil elastase inhibitors in liver disease
US20060177444A1 (en) Concomitant drug as therapeutic agent for inflammatory bowel disease
US20250281397A1 (en) Formulations of a plasma kallikrein inhibitor
US20230381162A1 (en) Treatments of angioedema
CN113993520A (zh) 血管性水肿的治疗
JP2003517443A (ja) 炎症性腸疾患を治療するための方法および組成物
JP2008515903A (ja) 拡張機能障害または拡張期心不全の予防または処置のためのレニン阻害剤の使用
US20100204286A1 (en) Method for reducing gastrointestinal adverse effects of cytotoxic agents
US20100035848A1 (en) Therapy for disorders of the proximal digestive tract
WO2022048618A1 (en) Methods to treat inflammatory bowel disease
RU2469724C2 (ru) Профилактическое или терапевтическое вещество при воспалительных болезнях кишечника
TW202308623A (zh) 用於預防或治療纖維化之醫藥組成物
JP2022069377A (ja) 血管性浮腫の処置
HK40086505A (zh) 治疗炎性肠病的方法
HK1250932A1 (en) Formulations containing diacerein and methods of lowering blood levels of uric acid using the same

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20130909